Evidence map›Paper›PMID 31518280›Full record

ArticleJMIR aging2019

A Rapid, Mobile Neurocognitive Screening Test to Aid in Identifying Cognitive Impairment and Dementia (BrainCheck): Cohort Study.

Samantha Groppell, Karina M Soto-Ruiz, Benjamin Flores, William Dawkins, Isabella Smith, David M Eagleman, Yael Katz

2 registry-linked trialsAbstract read
In one paragraph

Article in JMIR aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03608722 naunknown statusnot on this map

BrainCheck: Using Simple Video Games to Detect and Track Cognitive Health and Impairment

TypeinterventionalSponsorBrainCheck, Inc.Ran2015 to 2020Enrolled2,500ConditionsDementia, Mild Cognitive Impairment, Cognitive Impairment, Cognitive DeclineArmsSLUMS, MMSE, MoCA, BrainCheck
NCT06821087 phase2completednot on this mapstarted 2025, after this paper: background citation

Evaluating the Neuromodulatory Effect of Ketamine in Long COVID: A Pilot Study Targeting Fatigue and Neurocognitive Symptoms

TypeinterventionalSponsorUniversity of Texas at AustinRan2025 to 2026Enrolled20ConditionsLong COVIDArmsKetamine only
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Observational
  11. Cognitive Trajectories After Hospitalization for COVID-19: A 36-Month Longitudinal Study.The Journal of neuropsychiatry and clinical neurosciences · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Samantha Groppell *School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, United States.ORCID http://orcid.org/0000-0002-6625-3452
Karina M Soto-Ruiz *BrainCheck Inc, Houston, TX, United States.ORCID http://orcid.org/0000-0001-5190-0023
Benjamin Flores *BrainCheck Inc, Houston, TX, United States.ORCID http://orcid.org/0000-0002-1859-8237
William Dawkins *BrainCheck Inc, Houston, TX, United States.ORCID http://orcid.org/0000-0001-5048-7943
Isabella Smith *BrainCheck Inc, Houston, TX, United States.ORCID http://orcid.org/0000-0003-4892-9671
David M Eagleman *Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, United States.ORCID http://orcid.org/0000-0002-3120-7974
Yael Katz *BrainCheck Inc, Houston, TX, United States.ORCID http://orcid.org/0000-0001-8466-5760

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe US population over the age of 65 is expected to double by the year 2050. Concordantly, the incidence of dementia is projected to increase. The subclinical stage of dementia begins years before signs and symptoms appear. Early detection of cognitive impairment and/or cognitive decline may allow for interventions to slow its progression. Furthermore, early detection may allow for implementation of care plans that may affect the quality of life of those affected and their caregivers.

objectiveWe sought to determine the accuracy and validity of BrainCheck Memory as a diagnostic aid for age-related cognitive impairment, as compared against physician diagnosis and other commonly used neurocognitive screening tests, including the Saint Louis University Mental Status (SLUMS) exam, the Mini-Mental State Examination (MMSE), and the Montreal Cognitive Assessment (MoCA).

methodsWe tested 583 volunteers over the age of 49 from various community centers and living facilities in Houston, Texas. The volunteers were divided into five cohorts: a normative population and four comparison groups for the SLUMS exam, the MMSE, the MoCA, and physician diagnosis. Each comparison group completed their respective assessment and BrainCheck Memory.

resultsA total of 398 subjects were included in the normative population. A total of 84 participants were in the SLUMS exam cohort, 51 in the MMSE cohort, 35 in the MoCA cohort, and 18 in the physician cohort. BrainCheck Memory assessments were significantly correlated to the SLUMS exam, with coefficients ranging from .5 to .7. Correlation coefficients for the MMSE and BrainCheck and the MoCA and BrainCheck were also significant. Of the 18 subjects evaluated by a physician, 9 (50%) were healthy, 6 (33%) were moderately impaired, and 3 (17%) were severely impaired. A significant difference was found between the severely and moderately impaired subjects and the healthy subjects (P=.02). We derived a BrainCheck Memory composite score that showed stronger correlations with the standard assessments as compared to the individual BrainCheck assessments. Receiver operating characteristic (ROC) curve analysis of this composite score found a sensitivity of 81% and a specificity of 94%.

conclusionsBrainCheck Memory provides a sensitive and specific metric for age-related cognitive impairment in older adults, with the advantages of a mobile, digital, and easy-to-use test.

trial registrationClinicalTrials.gov NCT03608722; https://clinicaltrials.gov/ct2/show/NCT03608722 (Archived by WebCite at http://www.webcitation.org/76JLoYUGf).

Indexed as

Alzheimer’s diseaseBrainCheckcomputerized cognitive assessmentdementiadigital cognitive assessmentdigital testingelectronic neurocognitive toolsmild cognitive impairment (MCI)neurocognitive computerized assessment tools (NCAT)neurocognitive tests

Identifiers

PMID31518280
PMCPMC6715071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.